Furthermore, two phase III studies comparing gilteritinib and midostaurin in combination with standard chemotherapy are under investigation (NCT03836209 and NCT04027309) [24], as well as several clinical trials of gilteritinib combined with hypomethylating agents and/or venetoclax for the treatment of FLT3-mutated AML (NCT02752035, NCT03404193, and NCT05010122) [24]. This evidence concerns the gene FLT3 and acute myeloid leukemia.